Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastrointestinal Stromal Tumor (GIST): early-phase trial registry
5 of 7 indexed Gastrointestinal Stromal Tumor (GIST) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Gastrointestinal Stromal Tumor (GIST): 7 US clinical trials tracked, 5 recruiting.
Gastrointestinal Stromal Tumor (GIST) is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 2 of these trials.
Enrollment posture brief
Registry condition gastrointestinal-stromal-tumor-gist
OPEN 5 | RECR 71% | LATE 0 | EARLY 5 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Gastrointestinal Stromal Tumor (GIST) lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastrointestinal Stromal Tumor (GIST) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastrointestinal Stromal Tumor (GIST) is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastrointestinal Stromal Tumor (GIST) research.
Stanford University accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastrointestinal Stromal Tumor (GIST) enrolment sits around 120 participants.
Median target enrolment is 120 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.
-
Gastrointestinal Stromal Tumor (GIST) research is mostly interventional.
5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
National Cancer Institute (NCI)
NCT04557969
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
NCT05489237
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology
NCT06655246
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals
NCT06630234
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
NCT01048281
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
NCT01991379
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
NCT00780494
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastrointestinal Stromal Tumor (GIST) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastrointestinal Stromal Tumor (GIST) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastrointestinal Stromal Tumor (GIST) page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Gastrointestinal Stromal Tumor (GIST) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stanford University sponsors the most Gastrointestinal Stromal Tumor (GIST) trials on record, review their full trial history before evaluating a specific study. See Stanford University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Stromal Tumor (GIST) condition card totals 7 registered trials; most-linked intervention Imatinib Mesylate (Gleevec®; STI571; NSC #716051); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.